Cargando…

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. Results suggest that venetoclax is only active in a small cohort of patients therefore we wanted to determine its efficacy when used in combination. Combining...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matulis, Shannon M., Gupta, Vikas A., Nooka, Ajay K., Von Hollen, Hayley, Kaufman, Jonathan L., Lonial, Sagar, Boise, Lawrence H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874660/ https://www.ncbi.nlm.nih.gov/pubmed/26707935 http://dx.doi.org/10.1038/leu.2015.350

Ejemplares similares

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
por: Bajpai, Richa, et al.
Publicado: (2020)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
por: Gupta, Vikas A, et al.
Publicado: (2021)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Dimethylarsinothioyl Glutathione as a Metabolite in Human Multiple Myeloma Cell Lines upon Exposure to Darinaparsin
por: Yehiayan, Lucy, et al.
Publicado: (2014)

MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma
por: Wang, Dongxue, et al.
Publicado: (2017)

Alterations in Glutathione Levels and Apoptotic Regulators Are Associated with Acquisition of Arsenic Trioxide Resistance in Multiple Myeloma
por: Matulis, Shannon M., et al.
Publicado: (2012)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
por: Kaufman, Jonathan L., et al.
Publicado: (2019)

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
por: Maples, Kathryn T., et al.
Publicado: (2023)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
por: Robinson, M. Hope, et al.
Publicado: (2023)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
por: Mina, Roberto, et al.
Publicado: (2020)

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia
por: Gaudette, Brian T., et al.
Publicado: (2015)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
por: Deng, Jing, et al.
Publicado: (2017)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
por: Mikhael, Joseph, et al.
Publicado: (2018)

A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax
por: Downey-Kopyscinski, Sondra L., et al.
Publicado: (2022)

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
por: Shah, Nishi, et al.
Publicado: (2014)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
por: Soncini, Debora, et al.
Publicado: (2021)

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity
por: Moreno, Alberto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uq9g12kogm82lohsh6kc5vgnbb